When the human body enters critical illness, its emergency systems switch on with extraordinary force. The sympathetic nervous system floods the circulation with adrenaline and related catecholamines, accelerating the heartbeat, tightening blood vessels and redirecting blood toward organs considered essential for immediate survival. This response can stabilize blood pressure and preserve perfusion during the first stages of shock. But a new state-of-the-art review argues that the same biological system can become toxic when activated continuously, damaging the heart, disturbing immune function and worsening metabolic stress. The review, published in Intensive Care Medicine, examines whether beta-blockers—drugs best known for slowing the heart and lowering blood pressure—can safely interrupt this cycle in critically ill patients. Its conclusion is deliberately cautious: beta-blockade may be lifesaving in carefully selected situations, but applying it broadly in intensive care could remove the very cardiovascular compensation keeping a patient alive.

The central problem is that critical illness is not a single physiological condition. A patient with an acute myocardial infarction, a person in septic shock, someone with severe traumatic brain injury and a patient experiencing thyroid storm may all require intensive care, yet their circulatory systems can be operating in profoundly different ways. Beta-blockers prevent adrenaline and noradrenaline from activating beta-adrenergic receptors, particularly the β1 receptors concentrated in cardiac tissue. Blocking those receptors reduces heart rate and myocardial contractility, thereby lowering oxygen demand and limiting the damaging effects of excessive catecholamine exposure. Some agents also affect vascular tone or have additional receptor activity. In a patient whose heart is beating dangerously fast despite adequate circulation, this may restore efficiency. In a patient whose blood pressure depends on a rapid heartbeat and strong contractility, the same intervention may cause a sudden fall in cardiac output and organ perfusion.

The review, led by Marlies Ostermann of King’s College London and co-authored by an international group of intensive-care, cardiology, neurology and anesthesia specialists, describes adrenergic activation as a spectrum rather than a simple “high” or “low” state. Early sympathetic stimulation can be adaptive: tachycardia increases cardiac output, while vasoconstriction helps maintain arterial pressure. Persistent stimulation, however, can produce tachyarrhythmias, myocardial injury, impaired glucose and lipid metabolism, immune dysregulation and progressive organ dysfunction. At the cellular level, sustained beta-adrenergic signaling increases cyclic AMP and calcium handling in cardiomyocytes. Initially, this strengthens contraction. Over time, excessive calcium loading and heightened oxygen consumption can contribute to electrical instability, cellular injury and ventricular dysfunction. The biological challenge is therefore not merely to lower a number on a monitor, but to distinguish harmful adrenergic excess from a response that remains essential.

There are already several situations in which beta-blocker therapy has a well-established or clinically accepted role. After an acute myocardial infarction, reducing heart rate and contractility can decrease ischemic oxygen demand, although treatment must be avoided or delayed when cardiogenic shock is ongoing. Beta-blockers are also used to control selected tachyarrhythmias, including atrial fibrillation with a rapid ventricular response, and to manage some hypertensive emergencies. During thyroid storm, they blunt the cardiovascular consequences of excessive thyroid hormone activity, which sensitizes tissues to catecholamines. In cirrhosis, nonselective beta-blockers can reduce portal venous pressure and help prevent variceal bleeding. These applications share an important feature: the therapeutic target is relatively clear, and clinicians can balance the expected benefit against the patient’s hemodynamic reserve.

The most controversial arena is septic shock. Infection-driven inflammation can cause widespread vasodilation, capillary leakage and impaired oxygen utilization, forcing clinicians to use vasopressors such as norepinephrine to support blood pressure. Many patients with septic shock also develop persistent tachycardia. A fast heart rate may reduce the time available for ventricular filling, increase myocardial oxygen consumption and impair the efficiency of each heartbeat. Short-acting beta-blockers such as esmolol and landiolol have therefore attracted intense interest. Their rapid onset and short duration make it possible, at least in principle, to titrate treatment minute by minute. Some studies have reported improved hemodynamic measures or signals of benefit in highly selected patients with “hyperkinetic” shock—those with persistent tachycardia and apparently preserved cardiac output. Yet randomized trials and meta-analyses have produced conflicting results, including concern that landiolol may worsen organ failure in some patients. The evidence does not support treating tachycardia alone as an automatic indication.

That uncertainty reflects a technical issue at the heart of intensive-care medicine: heart rate is only one component of circulation. Cardiac output equals heart rate multiplied by stroke volume, but the relationship is not fixed. If a failing ventricle cannot eject enough blood with each contraction, a higher heart rate may temporarily sustain output. If stroke volume is adequate and the rate is excessively high, slowing the heart may improve filling and reduce oxygen consumption. Clinicians must also consider preload, vascular resistance, ventricular function, lactate trends, urine output, capillary refill and the doses of vasopressors and inotropes being administered. The review highlights physiological markers that might identify patients at risk of cardiovascular collapse after pharmacological heart-rate reduction, including arterial pressure features that reveal limited cardiac reserve. No single marker has yet become a universally reliable bedside test, however, and the heterogeneity of septic shock makes broad treatment targets difficult to define.

The same tension appears in other critical-care syndromes. Following traumatic brain injury, a powerful catecholamine surge can produce tachycardia, hypertension, inflammation and cardiac injury. Beta-blockade might protect the brain indirectly by reducing cardiovascular stress, and experimental work suggests that propranolol may influence inflammatory pathways and cerebral autoregulation. Observational studies have associated early treatment with improved outcomes in some populations, but randomized evidence remains limited and concerns persist about hypotension reducing cerebral perfusion. Severe burns can trigger prolonged hypermetabolism and adrenergic activation, raising the possibility that beta-blockers could reduce cardiac workload and metabolic demand. Again, studies suggest potential benefits, but patient selection, drug choice and timing vary substantially. In acute heart failure and cardiogenic shock, meanwhile, initiating or increasing beta-blockade can be dangerous when the heart is unable to maintain forward flow, even though abrupt withdrawal of chronic therapy may also carry risks.

The review emphasizes that the question is not simply whether beta-blockers work, but which beta-blocker, at what dose, at what moment and in which physiological phenotype. A short-acting, titratable intravenous drug is fundamentally different from a long-acting oral agent. A cardioselective beta1 blocker may have a different risk profile from a nonselective drug such as propranolol, particularly in patients with reactive airway disease. Continuing a patient’s established chronic therapy is not equivalent to starting treatment de novo during shock, and temporarily stopping a long-term prescription is not always benign. Withdrawal can produce rebound sympathetic activity, while re-initiation may be unsafe if cardiac output has deteriorated. Dose matters as well: a small reduction in excessive adrenergic drive could improve ventricular efficiency, whereas an overly aggressive dose could suppress compensatory responses. These distinctions are often lost when studies combine different drugs, doses, illness states and treatment goals under the single label of “beta-blockade.”

For now, the authors call for a phenotype-driven and physiology-guided strategy rather than routine beta-blocker use across the intensive-care unit. Future trials will need to define measurable treatment targets, establish monitoring strategies and separate patients according to the mechanisms driving their instability. They will also need to distinguish mortality from intermediate outcomes such as vasopressor exposure, arrhythmia burden, myocardial injury, renal function and neurological recovery. The review identifies a major gap in current practice: clinicians lack dependable indicators showing who is likely to benefit and who is likely to decompensate. Beta-blockers may eventually become a precision tool for controlling adrenergic toxicity, but they are not a universal antidote to critical illness. In the ICU, slowing a racing heart can be an elegant correction—or a dangerous removal of the body’s last reserve. The difference lies in reading the physiology before reaching for the drug.